Stephens has recently initiated Sensei Biotherapeutics Inc (SNSE) stock to Overweight rating, as announced on May 14, 2024, according to Finviz. Earlier, on July 1, 2021, Berenberg had reduced the stock from a Buy to Hold, setting a price target of $12. Oppenheimer also reduced Perform rating with a price target of $14. Additionally, Piper Sandler initiated Overweight rating on March 1, 2021, with a target price of $25. Oppenheimer analysts, in their report published on March 1, 2021, also initiated Outperform rating for Sensei Biotherapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sensei Biotherapeutics Inc (SNSE) Stock Trading Recap
On Tuesday, Sensei Biotherapeutics Inc (SNSE) stock saw a decline, ending the day at $0.62 which represents a decrease of $-0.16 or -20.51% from the prior close of $0.78. The stock opened at $0.65 and touched a low of $0.55 during the day, reaching a high of $0.71. The volume of shares traded was 1.82 million exceeding the average volume of 0.21 million.
Sponsored
SNSE Stock Performance and Moving Averages
In recent trading, Sensei Biotherapeutics Inc (SNSE) stock price has shown some volatility, fluctuating 33.72% over the last five trades and 24.34% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -37.68%, and it has plunged by -9.33% in the previous three months. Currently, SNSE is trading at 22.15%, 13.81%, and -23.24% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, SNSE, a Healthcare sector stock, is trading -67.95% below its 52-week high but remains 61.93% above its 52-week low. The Average True Range (ATR) (14 days) of 0.09 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Sensei Biotherapeutics Inc’s Profitability and Valuation Ratios
Sensei Biotherapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -37.68%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Sensei Biotherapeutics Inc’s market capitalization stands at $15.64 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 0.3, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 34.24% of Sensei Biotherapeutics Inc (SNSE)’s shares, while financial institutions hold 8.41%.
